Israeli Minister of Industry, Trade and Labor and Israeli Chief Scientist Visit BrainStorm

NEW YORK & PETACH TIKVAH, Israel--BrainStorm Cell Therapeutics Inc.(OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it received a visit today by the Israeli Minister of Industry, Trade and Labor, Mr. Binyamin Ben-Eliezer and the Israeli Chief Scientist, Dr. Eli Opper. The purpose of the visit was to review BrainStorm’s progress towards the start of its first clinical trials in ALS. Minister Ben-Eliezer and Dr. Opper met with BrainStorm’s management and scientific team during their visit and received a detailed presentation of the Company’s science from Professor Eldad Melamed, BrainStorm’s Chief Medical Advisor and Professor Daniel Offen, BrainStorm’s Chief Scientific advisor.

“We are very pleased with the visit by Minister Ben-Eliezer and Dr. Opper”

“We are very pleased with the visit by Minister Ben-Eliezer and Dr. Opper,” stated Rami Efrati, CEO of BrainStorm. “This is the first visit to BrainStorm by the Israeli Minister of Industry, Trade and Labor as well as the Israeli Chief Scientist. Over the last three years the Company has received grants for its continued development of its stem cell therapeutic products from the Office of the Chief Scientist of the Israel Ministry of Industry, Trade and Labor. The visit by Minister Ben-Eliezer and Dr. Opper signals the importance of the work we are doing at BrainStorm. We look forward to their continuing support as we prepare to begin our clinical trials in ALS this year.”

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.